Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. It also develops OT-101 for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. The company was founded in 1988 and is headquartered in Agoura Hills, CA.